The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1735
ISSUE1735
August 18, 2025
Mepolizumab (Nucala) for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Mepolizumab (Nucala) for COPD
August 18, 2025 (Issue: 1735)
Mepolizumab (Nucala – GSK), a subcutaneously
injected interleukin-5 (IL-5) antagonist, has been
approved by the FDA for add-on maintenance
treatment of adults who have inadequately controlled
chronic obstructive pulmonary disease (COPD) with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.